Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:LOGC LogicBio Therapeutics (LOGC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsEarningsInsider TradesOptions ChainShort InterestSustainabilityTrends About LogicBio Therapeutics Stock (NASDAQ:LOGC) 30 days 90 days 365 days Advanced Chart Ad TradingTips10 EV Stocks to Buy Right NowEV stocks are red hot. We’ve found TEN that we think will produce big wins for early investors. There’s no charge to view this report, so I urge everyone to check out the 10 stocks we’ve found as soon as possible.Click here to view all 10 stocks right away. Get LogicBio Therapeutics alerts:Sign Up Key Stats Today's Range$6.27▼$6.4950-Day Range$2.04▼$2.0752-Week Range$0.26▼$3.77Volume192,844 shsAverage Volume273,635 shsMarket Capitalization$167.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewLogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.Read More… 10 EV Stocks to Buy Right Now (Ad)EV stocks are red hot. We’ve found TEN that we think will produce big wins for early investors. There’s no charge to view this report, so I urge everyone to check out the 10 stocks we’ve found as soon as possible.Click here to view all 10 stocks right away. LogicBio Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks9th Percentile Overall ScoreLOGC MarketRank™: LogicBio Therapeutics scored higher than 9% of companies evaluated by MarketBeat, and ranked 208th out of 214 stocks in the retail/wholesale sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for LogicBio Therapeutics.Read more about LogicBio Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of LogicBio Therapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LogicBio Therapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLogicBio Therapeutics has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about LogicBio Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.93% of the float of LogicBio Therapeutics has been sold short.Short Interest Ratio / Days to CoverLogicBio Therapeutics has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.Change versus previous monthShort interest in LogicBio Therapeutics has recently increased by 25.00%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLogicBio Therapeutics does not currently pay a dividend.Dividend GrowthLogicBio Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.49 Percentage of Shares Shorted14.93% of the float of LogicBio Therapeutics has been sold short.Short Interest Ratio / Days to CoverLogicBio Therapeutics has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.Change versus previous monthShort interest in LogicBio Therapeutics has recently increased by 25.00%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A Search Interest4 people have searched for LOGC on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added LogicBio Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, LogicBio Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.10% of the stock of LogicBio Therapeutics is held by insiders.Percentage Held by Institutions46.05% of the stock of LogicBio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LogicBio Therapeutics' insider trading history. Receive LOGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LogicBio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LOGC Stock News HeadlinesLGCB Linkage Global IncSeptember 15, 2024 | seekingalpha.comContextLogic Inc. Reports Second-Quarter Financial ResultsAugust 8, 2024 | globenewswire.comCould TSLA reach $500 a share? Free ebook says it’s possible.Even though shares of Tesla are only up 3% this year, one man believes Tesla’s next bull run is just around the corner. In his professional opinion, the share price could reach $500 or more… Now, we understand that may seem far-fetched, but as you’ll see in his new ebook, it’s not as crazy as it may sound. In fact, he argues a Trump presidency could make it happen much faster than you might think. which is why we’re emailing you now… For the time being, he’s giving away his Tesla ebook for free. Inside explains how shares could reach $500 in the near future.November 5, 2024 | WealthPress (Ad)LogicBio Therapeutics, Inc. (LOGC)May 14, 2024 | finance.yahoo.comRVVTF Revive Therapeutics Ltd.March 27, 2024 | seekingalpha.comLogicBio's IPO: What You Need To KnowSeptember 24, 2023 | finance.yahoo.comRare Diseases Market is projected to grow at a CAGR of 12.27% by 2033: Visiongain Reports LtdMarch 31, 2023 | uk.finance.yahoo.comAlexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® TherapeuticsNovember 16, 2022 | finance.yahoo.comSee More Headlines LOGC Stock Analysis - Frequently Asked Questions How were LogicBio Therapeutics' earnings last quarter? LogicBio Therapeutics, Inc. (NASDAQ:LOGC) posted its earnings results on Thursday, August, 8th. The company reported ($0.50) earnings per share for the quarter. The company earned $7 million during the quarter. LogicBio Therapeutics had a negative net margin of 141.03% and a negative trailing twelve-month return on equity of 109.05%. When did LogicBio Therapeutics IPO? LogicBio Therapeutics (LOGC) raised $77 million in an IPO on Friday, October 19th 2018. The company issued 5,800,000 shares at a price of $12.50-$14.00 per share. Jefferies, Barclays and William Blair acted as the underwriters for the IPO and Chardan was co-manager. What other stocks do shareholders of LogicBio Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that LogicBio Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Ginkgo Bioworks (DNA), Luminar Technologies (LAZR), Toast (TOST) and Globant (GLOB). Company Calendar Last Earnings8/08/2024Today11/04/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorRetail/Wholesale Industry Catalog & mail - order houses Sub-IndustryN/A Current SymbolNASDAQ:LOGC CUSIPN/A CIK1664106 Webwww.logicbio.com Phone(617) 245-0399FaxN/AEmployees62Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($9.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-317,000,000.00 Net Margins-141.03% Pretax Margin-135.90% Return on Equity-109.05% Return on Assets-62.15% Debt Debt-to-Equity RatioN/A Current Ratio31.80 Quick Ratio31.80 Sales & Book Value Annual Sales$287 million Price / Sales0.58 Cash FlowN/A Price / Cash FlowN/A Book Value$8.96 per share Price / Book0.71Miscellaneous Outstanding Shares26,270,000Free Float24,147,000Market Cap$167.34 million OptionableOptionable Beta2.04 Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NASDAQ:LOGC) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LogicBio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LogicBio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.